Monoamine oxidase inhibitors (MAOIs) are an older class of antidepressants that work by blocking the enzyme monoamine oxidase, which normally breaks down serotonin, norepinephrine, and dopamine. By blocking this enzyme, MAOIs increase the availability of these neurotransmitters.
MAOIs are highly effective for some patients with treatment-resistant depression and atypical depression, but they require strict dietary restrictions (avoiding tyramine-containing foods) and careful monitoring for drug interactions. Common MAOIs include phenelzine (Nardil), tranylcypromine (Parnate), and selegiline (Emsam patch).
NeuroGlow does not prescribe MAOIs but can help patients evaluate whether Spravato or IV ketamine may be a better fit for their situation.
MAOIs (Monoamine Oxidase Inhibitors) are an older class of antidepressants used primarily for patients who have not responded to SSRIs and SNRIs. Common MAOIs include Nardil (phenelzine) and Parnate (tranylcypromine). They require dietary restrictions (avoiding tyramine-rich foods like aged cheeses) and have significant drug interactions, which is why prescribers usually exhaust other options first. Importantly, MAOIs cannot be combined safely with ketamine therapy due to risk of serotonin syndrome and hypertensive crisis. NeuroGlow screens for MAOI use during every patient intake.